

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **ANNOUNCEMENT**

## **ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE PROPOSED ISSUE OF A SHARES**

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (百奥赛图(北京)医药科技股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

References are made to the Company’s announcements dated March 6, 2023 and March 15, 2023 and circular dated March 31, 2023 containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Proposed Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that the Company has submitted the application materials in respect of the Proposed Issue of A Shares, including the A Share prospectus (the “**A Share Prospectus**”), to the Shanghai Stock Exchange, and has received a letter of acceptance issued by the Shanghai Stock Exchange in respect of the Company’s application for the Proposed Issue of A Shares on June 20, 2023. The A Share Prospectus will be published on the website of the Review and Approval of the Issuance and Listing of Stock on the Science and Technology Innovation Board of the Shanghai Stock Exchange (kcb.sse.com.cn), and will be published on the websites of the Stock Exchange and the Company on the same date pursuant to Rule 13.10B of the Listing Rules.

**As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.**

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**  
**Shen Yuelei**

*Chairman of the Board, Chief Executive Officer and Executive Director*

Hong Kong, June 20, 2023

*As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*